ClinicalTrials.gg
CompletedNCT04163991MIDORAUpdated Dec 17, 2024Results posted

A Study to Evaluate the Safety and Efficacy of VIB4920 in Participants With Rheumatoid Arthritis

A Phase 2 interventional study of VIB4920 and Placebo in Rheumatoid Arthritis, sponsored by Amgen. Completed at 25 sites in 2 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2024-12-17.

Sponsored by Amgen · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
78
Allocation
Randomized
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 57 studies in Arthritis, Rheumatoid by Amgen — 1 open to participants now, 1 under way, none of them phase 3. Arthritis, Rheumatoid · Amgen.

Enrollment
34th of 47
78 · median 211
Started
2019
the only one that year
Phase 2
14 of 57
1 open now
Registered
56th of 57
by date

Among the 57 studies in Arthritis, Rheumatoid by Amgen, this one is the 34th largest by enrollment of the 47 interventional ones that give a count, is the only one that started in 2019, is one of 14 in phase 2, and was the 56th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

1 of the 57 studies in Arthritis, Rheumatoid by Amgen is open now, in 10 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 57 studies in Arthritis, Rheumatoid by Amgen, or all of them as a file.
02

Study summary

The purpose of the study is to evaluate the efficacy, safety, and pharmacokinetics (PK) of VIB4920 (formerly MEDI4920) in adult participants with rheumatoid arthritis (RA).

Read the detailed description

The overall study period will be approximately 337 days. After a screening period of up to 28 days, the participants will be randomized in a 1:1:1:1:1 ratio to receive intravenous dose of VIB4920 and/or placebo in 5 cohorts. Participants are to be followed on their stable background anti-RA therapy at least through 12 weeks (Day 85), at which time rescue therapy may be instituted. All participants will be followed at least through the primary (interim) analysis (Day 113), and those who have not instituted rescue therapy will be followed through Day 309 to determine the duration of clinical response. The primary analysis will be after all participants have completed Day 113, and the final analysis will be after all participants have completed follow-up.

Study with completed results acquired from Horizon in 2024.

03

Conditions studied

  • Rheumatoid Arthritis

Keywords

  • Rheumatoid Arthritis
  • RA
  • VIB4920
  • MEDI4920
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Principal Inclusion Criteria:

  1. Male or female adults, >= 18 years of age at time of .
  2. Diagnosed with RA according to the European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) 2010 criteria >= 6 months prior to screening.
  3. Disease Activity Score in 28 Joints (DAS 28) using C-reactive Protein (DAS28-CRP) > 3.2 at screening with >= 4 tender joint count (TJC) and >= 4 swollen joint count (SJC) out of the 28 joints assessed for DAS28 present at screening and confirmed present at visit 2 prior to randomization.
  4. Positive for rheumatoid factor (RF) and/or anti-citrullinated protein antibodies (ACPA) at screening, in accordance with criteria at the central laboratory.
  5. Treated with methotrexate (MTX), with or without a concomitant conventional disease-modifying anti-rheumatic drug (cDMARD).
  6. Agreeing to use of protocol defined methods.

Principal Exclusion Criteria:

  1. Prior or current inflammatory joint disease other than RA.
  2. Severe interstitial lung disease.
  3. Prior receipt of any biologic B-cell-depleting therapy.
  4. Receipt of any anti - tumor necrosis factor alpha (TNF-α) biologic agent \< 8 weeks prior to screening.
  5. Receipt of any biologic disease-modifying anti-rheumatic drug (bDMARD) with a mechanism of action other than direct TNF-α blockade, \< 12 weeks or \< 5 half-lives of the drug prior to screening.
  6. Injectable or treatment with > 10 mg/day dose of oral prednisolone or equivalent within 4 weeks prior to screening.
  7. Previous treatment with anti-cluster of differentiation 40 ligand (0L) compounds at any time before randomization.
  8. , , or infection.
  9. Pregnant or lactating or planning to get pregnant during the duration of the study.
  10. Evidence of active tuberculosis (TB) or being at high risk for TB.
  11. History of more than one episode of herpes zoster in the 12 months prior to screening or any opportunistic infection in the 12 months prior to screening, excluding localized mucocutaneous candidiasis.
  12. Receipt of or live therapeutic infectious agent within the 4 weeks prior to screening.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
78 participants (actual)

Study arms

  • Experimental
    VIB4920 1500 mg 4 Times

    Participants receive intravenous (IV) infusion of VIB4920 1500 mg on Days 1, 15, 29, and 57

    Drug: VIB4920

  • Experimental
    VIB4920 1500 mg Twice

    Participants receive IV infusion of VIB4920 1500 mg on Days 1 and 57, placebo on Days 15 and 29.

    Drug: VIB4920 · Drug: Placebo

  • Experimental
    VIB4920 3000 mg Twice

    Participants receive IV infusion of VIB4920 3000 mg on Days 1 and 57, placebo on Days 15 and 29.

    Drug: VIB4920 · Drug: Placebo

  • Experimental
    VIB4920 3000 mg Once

    Participants receive IV infusion of VIB4920 3000 mg on Day 1 and placebo on Days 15, 29, and 57.

    Drug: VIB4920 · Drug: Placebo

  • Placebo comparator
    Placebo

    Participants receive IV infusion of placebo matched to VIB4920 on Days 1, 15, 29, and 57.

    Drug: Placebo

Interventions

  • liquid for IV infusion following dilution in normal saline

    Also known as: MEDI4920, dazodalibep

  • DrugPlacebo

    0.9% saline for IV infusion

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Day 113 in DAS28-CRP

    The DAS28-CRP is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100 mm), and high-sensitivity C-reactive protein (hsCRP; in mg/L). Scores on the DAS28-CRP range from 0 to approximately 10, where higher scores indicate more disease activity. A negative change from baseline indicates improvement in disease activity. Results are from a mixed-effect model for repeated measures (MMRM) analysis with treatment, visit, visit by treatment interaction, and baseline DAS28-CRP score included in the model.

    Time frame: Day 1 (Baseline), Day 113

  2. Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (TESAEs), and Treatment-emergent Adverse Events of Special Interest (TEAESIs)

    Adverse event (AE): any untoward medical occurrence associated with the use of an intervention in humans, whether or not it is considered intervention-related. Serious adverse event (SAE): an AE that results in any of the following outcomes: death; life-threatening AE; inpatient hospitalization or prolongation of existing hospitalization; persistent or significant incapacity; congenital anomaly/birth defect; other important medical event jeopardizing the participant's well-being. AEs of special interest (AESIs) include: thrombotic and embolic events; anaphylaxis and clinically significant (Common Terminology Criteria for Adverse Events \[CTCAE\] Grade 3 or higher) hypersensitivity reactions; severe infusion-related reactions (CTCAE Grade 3 or higher); immune complex disease; severe (CTCAE Grade 3 or higher) and/or opportunistic infections; hepatic function abnormality meeting the definition of Hy's Law; malignant neoplasm. (CTCAE Grade 3=Severe; Grade 4=Life-threatening; Grade 5=Fatal.)

    Time frame: From first dose of study drug through Day 309 ± 7 days

Secondary outcomes

  1. Pharmacokinetics (PK) of VIB4920: Maximum Observed Concentration (Cmax)

    Time frame: Predose (within 30 minutes prior to start of infusion), and within 10 minutes of the end of infusion on Days 1 (Dose 1), 15 ± 1 day (d; Dose 2), 29 ± 3d (Dose 3), 57 ± 3d (Dose 4), and Days 85 ± 3d, 113 ± 5d, 141 ± 5d, 169 ± 5d, 197 ± 7d, 225 ± 7d

  2. PK of VIB4920: Time to Cmax (Tmax)

    Time frame: Predose (within 30 minutes prior to start of infusion), and within 10 minutes of the end of infusion on Days 1 (Dose 1), 15 ± 1 day (d; Dose 2), 29 ± 3d (Dose 3), 57 ± 3d (Dose 4), and Days 85 ± 3d, 113 ± 5d, 141 ± 5d, 169 ± 5d, 197 ± 7d, 225 ± 7d

  3. PK of VIB4920: Area Under the Concentration-Time Curve From Time 0 to the Last Quantifiable Concentration (AUClast)

    Time frame: Predose (within 30 minutes prior to start of infusion), and within 10 minutes of the end of infusion on Days 1 (Dose 1), 15 ± 1 day (d; Dose 2), 29 ± 3d (Dose 3), 57 ± 3d (Dose 4), and Days 85 ± 3d, 113 ± 5d, 141 ± 5d, 169 ± 5d, 197 ± 7d, 225 ± 7d

  4. PK of VIB4920: Area Under the Concentration-Time Curve From Time 0 to Day 56 (AUC0-56D)

    Time frame: Predose (within 30 minutes prior to start of infusion), and within 10 minutes of the end of infusion on Days 1 (Dose 1), 15 ± 1 day (d; Dose 2), 29 ± 3d (Dose 3), Day 56

  5. PK of VIB4920: Total Body Clearance (CL) for Dose 1 and Total Body Clearance at Steady State (CLss) for Doses 2 to 4

    Time frame: Predose (within 30 minutes prior to start of infusion), and within 10 minutes of the end of infusion on Days 1 (Dose 1), 15 ± 1 day (d; Dose 2), 29 ± 3d (Dose 3), 57 ± 3d (Dose 4), and Days 85 ± 3d, 113 ± 5d, 141 ± 5d, 169 ± 5d, 197 ± 7d, 225 ± 7d

  6. PK of VIB4920: Terminal Elimination Half-Life (t1/2)

    Time frame: Predose (within 30 minutes prior to start of infusion), and within 10 minutes of the end of infusion on Days 1 (Dose 1), 15 ± 1 day (d; Dose 2), 29 ± 3d (Dose 3), 57 ± 3d (Dose 4), and Days 85 ± 3d, 113 ± 5d, 141 ± 5d, 169 ± 5d, 197 ± 7d, 225 ± 7d

  7. PK of VIB4920: Volume of Distribution at Steady State (Vss)

    Time frame: Predose (within 30 minutes prior to start of infusion), and within 10 minutes of the end of infusion on Days 1 (Dose 1), 15 ± 1 day (d; Dose 2), 29 ± 3d (Dose 3), 57 ± 3d (Dose 4), and Days 85 ± 3d, 113 ± 5d, 141 ± 5d, 169 ± 5d, 197 ± 7d, 225 ± 7d

  8. Total Soluble Cluster of Differentiation 40 Ligand (sCD40L) Plasma Concentration Over Time

    Total sCD40L (free sCD40L and sCD40L bound to VIB4920) was measured in plasma samples using a modified commercially available kit.

    Time frame: Day 1 (Baseline), Days 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309

  9. Percentage of Participants With Positive Anti-Drug Antibodies (ADA) to VIB4920

    ADA positive at any time: observed at least once during the study (baseline included). Treatment-emergent ADA: ADA positive post-baseline only or boosted pre-existing ADA during the study period. Persistent positive: treatment-induced ADA positive at ≥ 2 post-baseline assessments (with ≥ 16 weeks between first and last positive) or positive at last post-baseline assessment. Transient positive: treatment-induced ADA post-baseline positive but does not fulfill the criteria of persistent positive.

    Time frame: Day 1 (Baseline) to Day 309 Day 1 (Baseline) up to Day 309 (± 7 days)

  10. Change From Baseline to Day 113 in Anti-Citrullinated Protein Antibodies (ACPAs)

    Excluding data after rescue. Adjusted geometric mean ratio to baseline (90% CI) results are from MMRM analysis on log(ratio to baseline) with treatment, visit, visit by treatment interaction, and log(baseline) included in the model. Ratios less than 1 indicate a decrease.

    Time frame: Day 1 (Baseline), Day 113

  11. Change From Baseline to Day 113 in Rheumatoid Factor (RF)

    Excluding data after rescue. Adjusted geometric mean ratio to baseline (90% CI) results are from MMRM analysis on log(ratio to baseline) with treatment, visit, visit by treatment interaction, and log(baseline) included in the model. Ratios less than 1 indicate a decrease.

    Time frame: Day 1 (Baseline), Day 113

  12. Percentage of Participants With Clinical Remission at Day 113

    Clinical remission is defined as DAS28-CRP \< 2.6. The DAS28-CRP is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100 mm), and high-sensitivity C-reactive protein (hsCRP; in mg/L). Scores on the DAS28-CRP range from 0 to approximately 10, where higher scores indicate more disease activity.

    Time frame: Day 113

  13. Time to Start of New Treatment for Rheumatoid Arthritis (Rescue Medication)

    Based on Kaplan-Meier method.

    Time frame: Day 1 (Baseline) up to Day 309 (± 7 days)

07

Results

Posted Feb 14, 2023

Participant flow

Participant flow — Overall Study
MilestonePlaceboVIB4920 3000 mg OnceVIB4920 1500 mg TwiceVIB4920 3000 mg TwiceVIB4920 1500 mg 4 Times
Started1616161515
Completed1513111214
Not completed13531
Withdrew: Adverse event00010
Withdrew: Death00100
Withdrew: Lost to follow-up01000
Withdrew: Withdrawal by subject11311
Withdrew: Other, not specified01110

Outcome measures

PrimaryChange From Baseline to Day 113 in DAS28-CRP

The DAS28-CRP is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100 mm), and high-sensitivity C-reactive protein (hsCRP; in mg/L). Scores on the DAS28-CRP range from 0 to approximately 10, where higher scores indicate more disease activity. A negative change from baseline indicates improvement in disease activity. Results are from a mixed-effect model for repeated measures (MMRM) analysis with treatment, visit, visit by treatment interaction, and baseline DAS28-CRP score included in the model.

Time frame:
Day 1 (Baseline), Day 113
Reported as:
Least squares mean · score on a scale
Change From Baseline to Day 113 in DAS28-CRP
score on a scalePlaceboVIB4920 3000 mg OnceVIB4920 1500 mg TwiceVIB4920 3000 mg TwiceVIB4920 1500 mg 4 Times
Change From Baseline to Day 113 in DAS28-CRP-1.06 ± 0.26-1.90 ± 0.27-1.87 ± 0.27-1.87 ± 0.27-1.83 ± 0.28
Statistical analysis
  • Placebo vs VIB4920 3000 mg Once · MMRM · p = 0.0296 (Results are from MMRM analysis with treatment, visit, visit by treatment interaction, and baseline DAS28-CRP score included in the model.) · Least squares (ls) mean difference: -0.84 · 90% CI -1.47 to -0.21LS Mean difference is VIB4920 minus placebo. Differences less than 0 favor VIB4920.
  • Placebo vs VIB4920 1500 mg Twice · MMRM · p = 0.0355 (Results are from MMRM analysis with treatment, visit, visit by treatment interaction, and baseline DAS28-CRP score included in the model.) · Ls mean difference: -0.81 · 90% CI -1.44 to -0.18LS Mean difference is VIB4920 minus placebo. Differences less than 0 favor VIB4920.
  • Placebo vs VIB4920 3000 mg Twice · MMRM · p = 0.0364 (Results are from MMRM analysis with treatment, visit, visit by treatment interaction, and baseline DAS28-CRP score included in the model.) · Ls mean difference: -0.81 · 90% CI -1.44 to -0.18LS Mean difference is VIB4920 minus placebo. Differences less than 0 favor VIB4920.
  • Placebo vs VIB4920 1500 mg 4 Times · MMRM · p = 0.0478 (Results are from MMRM analysis with treatment, visit, visit by treatment interaction, and baseline DAS28-CRP score included in the model.) · Ls mean difference: -0.77 · 90% CI -1.41 to -0.13LS Mean difference is VIB4920 minus placebo. Differences less than 0 favor VIB4920.
PrimaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (TESAEs), and Treatment-emergent Adverse Events of Special Interest (TEAESIs)

Adverse event (AE): any untoward medical occurrence associated with the use of an intervention in humans, whether or not it is considered intervention-related. Serious adverse event (SAE): an AE that results in any of the following outcomes: death; life-threatening AE; inpatient hospitalization or prolongation of existing hospitalization; persistent or significant incapacity; congenital anomaly/birth defect; other important medical event jeopardizing the participant's well-being. AEs of special interest (AESIs) include: thrombotic and embolic events; anaphylaxis and clinically significant (Common Terminology Criteria for Adverse Events \[CTCAE\] Grade 3 or higher) hypersensitivity reactions; severe infusion-related reactions (CTCAE Grade 3 or higher); immune complex disease; severe (CTCAE Grade 3 or higher) and/or opportunistic infections; hepatic function abnormality meeting the definition of Hy's Law; malignant neoplasm. (CTCAE Grade 3=Severe; Grade 4=Life-threatening; Grade 5=Fatal.)

Time frame:
From first dose of study drug through Day 309 ± 7 days
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (TESAEs), and Treatment-emergent Adverse Events of Special Interest (TEAESIs)
ParticipantsPlaceboVIB4920 3000 mg OnceVIB4920 1500 mg TwiceVIB4920 3000 mg TwiceVIB4920 1500 mg 4 Times
At least one event1010141111
At least one study drug-related event43422
At least one event of ≥ Grade 3 severity01100
Death (Grade 5 severity)00100
At least one serious event01101
At least one serious and/or ≥ Grade 3 severity event01100
At least one related serious event00000
At least one event leading to discontinuation of study drug01000
At least one event of special interest01100
SecondaryPharmacokinetics (PK) of VIB4920: Maximum Observed Concentration (Cmax)
Time frame:
Predose (within 30 minutes prior to start of infusion), and within 10 minutes of the end of infusion on Days 1 (Dose 1), 15 ± 1 day (d; Dose 2), 29 ± 3d (Dose 3), 57 ± 3d (Dose 4), and Days 85 ± 3d, 113 ± 5d, 141 ± 5d, 169 ± 5d, 197 ± 7d, 225 ± 7d
Reported as:
Mean · μg/mL
Pharmacokinetics (PK) of VIB4920: Maximum Observed Concentration (Cmax)
μg/mLVIB4920 3000 mg OnceVIB4920 1500 mg TwiceVIB4920 3000 mg TwiceVIB4920 1500 mg 4 Times
Dose 1877 ± 204476 ± 127860 ± 275421 ± 102
Dose 2—504 ± 1621050 ± 349564 ± 163
Dose 3———601 ± 181
Dose 4———568 ± 140
SecondaryPK of VIB4920: Time to Cmax (Tmax)
Time frame:
Predose (within 30 minutes prior to start of infusion), and within 10 minutes of the end of infusion on Days 1 (Dose 1), 15 ± 1 day (d; Dose 2), 29 ± 3d (Dose 3), 57 ± 3d (Dose 4), and Days 85 ± 3d, 113 ± 5d, 141 ± 5d, 169 ± 5d, 197 ± 7d, 225 ± 7d
Reported as:
Median · day
PK of VIB4920: Time to Cmax (Tmax)
dayVIB4920 3000 mg OnceVIB4920 1500 mg TwiceVIB4920 3000 mg TwiceVIB4920 1500 mg 4 Times
Dose 10.0899 (0.0868 to 0.100)0.0875 (0.0847 to 0.0951)0.0875 (0.0840 to 0.0917)0.0903 (0.0840 to 0.108)
Dose 2—0.0681 (0.0646 to 0.0847)0.0667 (0.0486 to 0.0882)0.0486 (0.0437 to 0.0521)
Dose 3———0.0472 (0.0438 to 0.0486)
Dose 4———0.0667 (0.0486 to 0.0708)
SecondaryPK of VIB4920: Area Under the Concentration-Time Curve From Time 0 to the Last Quantifiable Concentration (AUClast)
Time frame:
Predose (within 30 minutes prior to start of infusion), and within 10 minutes of the end of infusion on Days 1 (Dose 1), 15 ± 1 day (d; Dose 2), 29 ± 3d (Dose 3), 57 ± 3d (Dose 4), and Days 85 ± 3d, 113 ± 5d, 141 ± 5d, 169 ± 5d, 197 ± 7d, 225 ± 7d
Reported as:
Mean · μg·day/mL
PK of VIB4920: Area Under the Concentration-Time Curve From Time 0 to the Last Quantifiable Concentration (AUClast)
μg·day/mLVIB4920 3000 mg OnceVIB4920 1500 mg TwiceVIB4920 3000 mg TwiceVIB4920 1500 mg 4 Times
Dose 17350 ± 13803980 ± 15807870 ± 25702960 ± 604
Dose 2—5280 ± 200010000 ± 33204060 ± 1290
Dose 3———6350 ± 1840
Dose 4———5770 ± 1110
SecondaryPK of VIB4920: Area Under the Concentration-Time Curve From Time 0 to Day 56 (AUC0-56D)
Time frame:
Predose (within 30 minutes prior to start of infusion), and within 10 minutes of the end of infusion on Days 1 (Dose 1), 15 ± 1 day (d; Dose 2), 29 ± 3d (Dose 3), Day 56
Reported as:
Mean · μg·day/mL
PK of VIB4920: Area Under the Concentration-Time Curve From Time 0 to Day 56 (AUC0-56D)
μg·day/mLVIB4920 3000 mg OnceVIB4920 1500 mg TwiceVIB4920 3000 mg TwiceVIB4920 1500 mg 4 Times
Dose 17280 ± 13704280 ± 12807870 ± 2570—
Dose 2—5310 ± 20009910 ± 3250—
SecondaryPK of VIB4920: Total Body Clearance (CL) for Dose 1 and Total Body Clearance at Steady State (CLss) for Doses 2 to 4
Time frame:
Predose (within 30 minutes prior to start of infusion), and within 10 minutes of the end of infusion on Days 1 (Dose 1), 15 ± 1 day (d; Dose 2), 29 ± 3d (Dose 3), 57 ± 3d (Dose 4), and Days 85 ± 3d, 113 ± 5d, 141 ± 5d, 169 ± 5d, 197 ± 7d, 225 ± 7d
Reported as:
Mean · mL/day
PK of VIB4920: Total Body Clearance (CL) for Dose 1 and Total Body Clearance at Steady State (CLss) for Doses 2 to 4
mL/dayVIB4920 3000 mg OnceVIB4920 1500 mg TwiceVIB4920 3000 mg TwiceVIB4920 1500 mg 4 Times
Dose 1 (CL)430 ± 91.9371 ± 92.5417 ± 144—
Dose 2 (CLss)—314 ± 104340 ± 140—
Dose 4 (CLss)———294 ± 49.8
SecondaryPK of VIB4920: Terminal Elimination Half-Life (t1/2)
Time frame:
Predose (within 30 minutes prior to start of infusion), and within 10 minutes of the end of infusion on Days 1 (Dose 1), 15 ± 1 day (d; Dose 2), 29 ± 3d (Dose 3), 57 ± 3d (Dose 4), and Days 85 ± 3d, 113 ± 5d, 141 ± 5d, 169 ± 5d, 197 ± 7d, 225 ± 7d
Reported as:
Mean · day
PK of VIB4920: Terminal Elimination Half-Life (t1/2)
dayVIB4920 3000 mg OnceVIB4920 1500 mg TwiceVIB4920 3000 mg TwiceVIB4920 1500 mg 4 Times
Dose 19.27 ± 1.619.06 ± 1.989.02 ± 1.06—
Dose 2—9.55 ± 1.519.88 ± 1.41—
Dose 4———10.5 ± 2.06
SecondaryPK of VIB4920: Volume of Distribution at Steady State (Vss)
Time frame:
Predose (within 30 minutes prior to start of infusion), and within 10 minutes of the end of infusion on Days 1 (Dose 1), 15 ± 1 day (d; Dose 2), 29 ± 3d (Dose 3), 57 ± 3d (Dose 4), and Days 85 ± 3d, 113 ± 5d, 141 ± 5d, 169 ± 5d, 197 ± 7d, 225 ± 7d
Reported as:
Mean · mL
PK of VIB4920: Volume of Distribution at Steady State (Vss)
mLVIB4920 3000 mg OnceVIB4920 1500 mg TwiceVIB4920 3000 mg TwiceVIB4920 1500 mg 4 Times
Dose 14350 ± 13003750 ± 6014540 ± 1470—
Dose 2—3490 ± 9263600 ± 1720—
Dose 4———3210 ± 865
SecondaryTotal Soluble Cluster of Differentiation 40 Ligand (sCD40L) Plasma Concentration Over Time

Total sCD40L (free sCD40L and sCD40L bound to VIB4920) was measured in plasma samples using a modified commercially available kit.

Time frame:
Day 1 (Baseline), Days 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309
Reported as:
Mean · ng/mL
Total Soluble Cluster of Differentiation 40 Ligand (sCD40L) Plasma Concentration Over Time
ng/mLPlaceboVIB4920 3000 mg OnceVIB4920 1500 mg TwiceVIB4920 3000 mg TwiceVIB4920 1500 mg 4 Times
Change at Day 154.6759 ± 3.659630.7744 ± 7.495436.0088 ± 14.432428.2492 ± 10.425233.9007 ± 8.7777
Change at Day 294.8431 ± 3.377067.5427 ± 16.432266.7047 ± 15.370868.0636 ± 28.652368.1386 ± 12.1314
Change at Day 570.8150 ± 1.605364.4177 ± 16.432262.5560 ± 14.444563.6939 ± 25.550064.1329 ± 12.4842
Change at Day 850.4483 ± 1.184253.1583 ± 20.651377.5360 ± 18.744057.2587 ± 20.074269.8821 ± 19.2623
Change at Day 1130.3420 ± 1.324621.4686 ± 19.370575.4407 ± 18.292153.4514 ± 26.271268.5636 ± 19.3458
Change at Day 1410.2547 ± 0.98631.6517 ± 3.756555.4204 ± 28.947053.2827 ± 31.616552.3943 ± 29.4422
Change at Day 1690.3114 ± 1.16530 ± 021.1296 ± 27.197318.3170 ± 20.284223.5727 ± 26.0510
Change at Day 1970.2757 ± 1.03160 ± 04.4354 ± 9.91462.5057 ± 4.48804.6343 ± 5.3603
Change at Day 2250.2450 ± 0.91670 ± 0-0.4043 ± 1.5127-0.0137 ± 1.1940-0.2971 ± 0.8718
Change at Day 2530.3436 ± 1.28553.1418 ± 11.7555-0.5946 ± 2.1439-0.5292 ± 1.9082-0.9485 ± 2.3281
Change at Day 281-0.0343 ± 0.12830 ± 0-0.5640 ± 1.7835-0.4729 ± 1.7693-0.9485 ± 2.3281
Change at Day 309-0.5654 ± 2.11540 ± 0-0.5720 ± 1.8088-0.7833 ± 2.7135-0.9485 ± 2.3281
SecondaryPercentage of Participants With Positive Anti-Drug Antibodies (ADA) to VIB4920

ADA positive at any time: observed at least once during the study (baseline included). Treatment-emergent ADA: ADA positive post-baseline only or boosted pre-existing ADA during the study period. Persistent positive: treatment-induced ADA positive at ≥ 2 post-baseline assessments (with ≥ 16 weeks between first and last positive) or positive at last post-baseline assessment. Transient positive: treatment-induced ADA post-baseline positive but does not fulfill the criteria of persistent positive.

Time frame:
Day 1 (Baseline) to Day 309 Day 1 (Baseline) up to Day 309 (± 7 days)
Reported as:
Number · percentage of participants
Percentage of Participants With Positive Anti-Drug Antibodies (ADA) to VIB4920
percentage of participantsVIB4920 3000 mg OnceVIB4920 1500 mg TwiceVIB4920 3000 mg TwiceVIB4920 1500 mg 4 Times
ADA positive at any time44.411.838.528.6
Baseline ADA positive0000
Baseline only ADA positive0000
Post-baseline ADA positive44.411.838.528.6
Treatment-emergent ADA44.411.838.528.6
Persistent positive11.1000
Transient positive33.311.838.528.6
SecondaryChange From Baseline to Day 113 in Anti-Citrullinated Protein Antibodies (ACPAs)

Excluding data after rescue. Adjusted geometric mean ratio to baseline (90% CI) results are from MMRM analysis on log(ratio to baseline) with treatment, visit, visit by treatment interaction, and log(baseline) included in the model. Ratios less than 1 indicate a decrease.

Time frame:
Day 1 (Baseline), Day 113
Reported as:
Geometric mean · ratio
Change From Baseline to Day 113 in Anti-Citrullinated Protein Antibodies (ACPAs)
ratioPlaceboVIB4920 3000 mg OnceVIB4920 1500 mg TwiceVIB4920 3000 mg TwiceVIB4920 1500 mg 4 Times
Change From Baseline to Day 113 in Anti-Citrullinated Protein Antibodies (ACPAs)1.08 (0.83 to 1.42)0.69 (0.52 to 0.91)0.82 (0.62 to 1.07)0.84 (0.63 to 1.11)0.62 (0.47 to 0.82)
Statistical analysis
  • Placebo vs VIB4920 3000 mg Once · MMRM · p = 0.0584 (Results are from MMRM analysis on log(ratio to baseline) with treatment, visit, visit by treatment interaction, and log(baseline) included in the model.) · Ratio of geometric mean versus placebo: 0.64 · 90% CI 0.43 to 0.94Ratio of geometric mean is for VIB4920:placebo. Ratios less than 1 indicate a decrease.
  • Placebo vs VIB4920 1500 mg Twice · MMRM · p = 0.2274 (Results are from MMRM analysis on log(ratio to baseline) with treatment, visit, visit by treatment interaction, and log(baseline) included in the model.) · Ratio of geometric mean versus placebo: 0.76 · 90% CI 0.51 to 1.11Ratio of geometric mean is for VIB4920:placebo. Ratios less than 1 indicate a decrease.
  • Placebo vs VIB4920 3000 mg Twice · MMRM · p = 0.2794 (Results are from MMRM analysis on log(ratio to baseline) with treatment, visit, visit by treatment interaction, and log(baseline) included in the model.) · Ratio of geometric mean versus placebo: 0.77 · 90% CI 0.52 to 1.14Ratio of geometric mean is for VIB4920:placebo. Ratios less than 1 indicate a decrease.
  • Placebo vs VIB4920 1500 mg 4 Times · MMRM · p = 0.0199 (Results are from MMRM analysis on log(ratio to baseline) with treatment, visit, visit by treatment interaction, and log(baseline) included in the model.) · Ratio of geometric mean versus placebo: 0.57 · 90% CI 0.39 to 0.85Ratio of geometric mean is for VIB4920:placebo. Ratios less than 1 indicate a decrease.
SecondaryChange From Baseline to Day 113 in Rheumatoid Factor (RF)

Excluding data after rescue. Adjusted geometric mean ratio to baseline (90% CI) results are from MMRM analysis on log(ratio to baseline) with treatment, visit, visit by treatment interaction, and log(baseline) included in the model. Ratios less than 1 indicate a decrease.

Time frame:
Day 1 (Baseline), Day 113
Reported as:
Geometric mean · ratio
Change From Baseline to Day 113 in Rheumatoid Factor (RF)
ratioPlaceboVIB4920 3000 mg OnceVIB4920 1500 mg TwiceVIB4920 3000 mg TwiceVIB4920 1500 mg 4 Times
Change From Baseline to Day 113 in Rheumatoid Factor (RF)1.20 (1.04 to 1.39)0.77 (0.66 to 0.89)0.74 (0.64 to 0.86)0.72 (0.62 to 0.84)0.57 (0.49 to 0.66)
Statistical analysis
  • Placebo vs VIB4920 3000 mg Once · MMRM · p = 0.0007 (Results are from MMRM analysis on log(ratio to baseline) with treatment, visit, visit by treatment interaction, and log(baseline) included in the model.) · Ratio of geometric mean versus placebo: 0.64 · 90% CI 0.52 to 0.79Ratio of geometric mean is for VIB4920:placebo. Ratios less than 1 indicate a decrease.
  • Placebo vs VIB4920 1500 mg Twice · MMRM · p = 0.0003 (Results are from MMRM analysis on log(ratio to baseline) with treatment, visit, visit by treatment interaction, and log(baseline) included in the model.) · Ratio of geometric mean versus placebo: 0.62 · 90% CI 0.50 to 0.76Ratio of geometric mean is for VIB4920:placebo. Ratios less than 1 indicate a decrease.
  • Placebo vs VIB4920 3000 mg Twice · MMRM · p = 0.0001 (Results are from MMRM analysis on log(ratio to baseline) with treatment, visit, visit by treatment interaction, and log(baseline) included in the model.) · Ratio of geometric mean versus placebo: 0.60 · 90% CI 0.48 to 0.74Ratio of geometric mean is for VIB4920:placebo. Ratios less than 1 indicate a decrease.
  • Placebo vs VIB4920 1500 mg 4 Times · MMRM · p = < 0.0001 (Results are from MMRM analysis on log(ratio to baseline) with treatment, visit, visit by treatment interaction, and log(baseline) included in the model.) · Ratio of geometric mean versus placebo: 0.47 · 90% CI 0.38 to 0.59Ratio of geometric mean is for VIB4920:placebo. Ratios less than 1 indicate a decrease.
SecondaryPercentage of Participants With Clinical Remission at Day 113

Clinical remission is defined as DAS28-CRP \< 2.6. The DAS28-CRP is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100 mm), and high-sensitivity C-reactive protein (hsCRP; in mg/L). Scores on the DAS28-CRP range from 0 to approximately 10, where higher scores indicate more disease activity.

Time frame:
Day 113
Reported as:
Number · percentage of participants
Percentage of Participants With Clinical Remission at Day 113
percentage of participantsPlaceboVIB4920 3000 mg OnceVIB4920 1500 mg TwiceVIB4920 3000 mg TwiceVIB4920 1500 mg 4 Times
Percentage of Participants With Clinical Remission at Day 11318.818.86.313.313.3
Statistical analysis
  • Placebo vs VIB4920 3000 mg Once · Regression, Logistic · p = 0.7750 (Results are from logistic regression analysis with treatment and baseline DAS28-CRP score included in the model.) · Odds ratio (or): 1.4 · 90% CI 0.2 to 8.0Odds ratio is VIB4920/placebo, with associated 90% CI and p-value. Odds ratios greater than 1 favor VIB4920.
  • Placebo vs VIB4920 1500 mg Twice · Regression, Logistic · p = 0.6974 (Results are from logistic regression analysis with treatment and baseline DAS28-CRP score included in the model.) · Odds ratio (or): 0.6 · 90% CI 0.1 to 5.5(Lower limit of 90% CI is \< 0.1.) Odds ratio is VIB4920/placebo, with associated 90% CI and p-value. Odds ratios greater than 1 favor VIB4920.
  • Placebo vs VIB4920 3000 mg Twice · Regression, Logistic · p = 0.9318 (Results are from logistic regression analysis with treatment and baseline DAS28-CRP score included in the model.) · Odds ratio (or): 0.9 · 90% CI 0.1 to 5.7Odds ratio is VIB4920/placebo, with associated 90% CI and p-value. Odds ratios greater than 1 favor VIB4920.
  • Placebo vs VIB4920 1500 mg 4 Times · Regression, Logistic · p = 0.9108 (Results are from logistic regression analysis with treatment and baseline DAS28-CRP score included in the model.) · Odds ratio (or): 0.9 · 90% CI 0.2 to 5.1Odds ratio is VIB4920/placebo, with associated 90% CI and p-value. Odds ratios greater than 1 favor VIB4920.
SecondaryTime to Start of New Treatment for Rheumatoid Arthritis (Rescue Medication)

Based on Kaplan-Meier method.

Time frame:
Day 1 (Baseline) up to Day 309 (± 7 days)
Reported as:
Median · days
Time to Start of New Treatment for Rheumatoid Arthritis (Rescue Medication)
daysPlaceboVIB4920 3000 mg OnceVIB4920 1500 mg TwiceVIB4920 3000 mg TwiceVIB4920 1500 mg 4 Times
Time to Start of New Treatment for Rheumatoid Arthritis (Rescue Medication)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (196 to NA)
Statistical analysis
  • Placebo vs VIB4920 3000 mg Once · Regression, Cox · p = 0.9805 (Based on Cox regression method with treatment group included in the model.) · Hazard ratio (hr): 1.04 · 90% CI 0.10 to 10.60Hazard ratio is VIB4920/placebo. Hazard ratios less than 1 favor VIB4920.
  • Placebo vs VIB4920 1500 mg Twice · Regression, Cox · p = 0.9805 (Based on Cox regression method with treatment group included in the model.) · Hazard ratio (hr): 1.04 · 90% CI 0.10 to 10.60Hazard ratio is VIB4920/placebo. Hazard ratios less than 1 favor VIB4920.
  • Placebo vs VIB4920 3000 mg Twice · Regression, Cox · p = 0.3407 (Based on Cox regression method with treatment group included in the model.) · Hazard ratio (hr): 3.01 · 90% CI 0.45 to 20.09Hazard ratio is VIB4920/placebo. Hazard ratios less than 1 favor VIB4920.
  • Placebo vs VIB4920 1500 mg 4 Times · Regression, Cox · p = 0.9805 (Based on Cox regression method with treatment group included in the model.) · Hazard ratio (hr): 1.04 · 90% CI 0.10 to 10.60Hazard ratio is VIB4920/placebo. Hazard ratios less than 1 favor VIB4920.

Adverse events

Collected over From screening (all cause mortality) or first dose of study drug (adverse events) through through Day 309 ± 7 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/16 (0%)0/16 (0%)10/16 (62.5%)
VIB4920 3000 mg Once0/18 (0%)1/18 (5.6%)10/18 (55.6%)
VIB4920 1500 mg Twice1/17 (5.9%)1/17 (5.9%)14/17 (82.4%)
VIB4920 3000 mg Twice0/13 (0%)0/13 (0%)11/13 (84.6%)
VIB4920 1500 mg 4 Times0/14 (0%)1/14 (7.1%)10/14 (71.4%)
Most frequent serious events
Most frequent serious events
EventPlaceboVIB4920 3000 mg OnceVIB4920 1500 mg TwiceVIB4920 3000 mg TwiceVIB4920 1500 mg 4 Times
NephrolithiasisRenal and urinary disorders0/160/180/170/131/14
DeathGeneral disorders0/160/181/170/130/14
COVID-19 pneumoniaInfections and infestations0/160/181/170/130/14
COVID-19Infections and infestations0/161/180/170/130/14
Most frequent other events
Showing 10 of 71
Most frequent other events
EventPlaceboVIB4920 3000 mg OnceVIB4920 1500 mg TwiceVIB4920 3000 mg TwiceVIB4920 1500 mg 4 Times
Upper respiratory tract infectionInfections and infestations1/161/180/173/130/14
OsteoarthritisMusculoskeletal and connective tissue disorders0/160/180/173/130/14
COVID-19Infections and infestations1/161/183/170/133/14
Rheumatoid arthritisMusculoskeletal and connective tissue disorders1/160/183/172/131/14
PharyngitisInfections and infestations0/160/180/172/131/14
CystitisInfections and infestations2/160/180/170/131/14
Urinary tract infectionInfections and infestations2/160/181/170/130/14
LymphopeniaBlood and lymphatic system disorders0/160/182/170/130/14
Alanine aminotransferase increasedInvestigations0/161/182/171/130/14
Aspartate aminotransferase increasedInvestigations0/160/182/170/130/14

Baseline characteristics

Full Analysis Set: all randomized participants who received any dose of study drug, analyzed according to the treatment randomized.

Age, Continuous
Age, Continuous(years)PlaceboVIB4920 3000 mg OnceVIB4920 1500 mg TwiceVIB4920 3000 mg TwiceVIB4920 1500 mg 4 TimesTotal
Mean56.3 ± 14.053.2 ± 10.759.0 ± 12.256.5 ± 12.256.4 ± 15.256.3 ± 12.7
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboVIB4920 3000 mg OnceVIB4920 1500 mg TwiceVIB4920 3000 mg TwiceVIB4920 1500 mg 4 TimesTotal
Female121411131262
Male4252316
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboVIB4920 3000 mg OnceVIB4920 1500 mg TwiceVIB4920 3000 mg TwiceVIB4920 1500 mg 4 TimesTotal
Hispanic or Latino111003
Not Hispanic or Latino151515151575
Unknown or Not Reported000000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboVIB4920 3000 mg OnceVIB4920 1500 mg TwiceVIB4920 3000 mg TwiceVIB4920 1500 mg 4 TimesTotal
Black or African American200114
White141615141473
Other, Not Specified001001
Disease Activity Score 28 C-reactive Protein (DAS28-CRP)
Disease Activity Score 28 C-reactive Protein (DAS28-CRP)(score on a scale)PlaceboVIB4920 3000 mg OnceVIB4920 1500 mg TwiceVIB4920 3000 mg TwiceVIB4920 1500 mg 4 TimesTotal
Mean5.443 ± 1.0665.473 ± 0.8835.945 ± 0.7365.452 ± 0.6445.761 ± 0.7115.615 ± 0.830
08

Study locations

25 sites
  • Research Site
    Anniston, Alabama 36207, United States
  • Research Site
    Sun City, Arizona 85704, United States
  • Research Site
    Upland, California 91786, United States
  • Research Site
    Clearwater, Florida 33765, United States
  • Research Site
    Margate, Florida 33063, United States
  • Research Site
    Miami Lakes, Florida 33014, United States
  • Research Site
    Zephyrhills, Florida 33542, United States
  • Research Site
    Atlanta, Georgia 30342, United States
  • Research Site
    Lexington, Kentucky 40504, United States
  • Research Site
    Wheaton, Maryland 20902, United States
  • Research Site
    Charlotte, North Carolina 28210, United States
  • Research Site
    Rocky Mount, North Carolina 27804, United States
  • Research Site
    Salisbury, North Carolina 28144, United States
  • Research Site
    Vandalia, Ohio 45377, United States
  • Research Site
    Norman, Oklahoma 73069, United States
  • Research Site
    Duncansville, Pennsylvania 16635, United States
  • Research Site
    Baytown, Texas 77477, United States
  • Research Site
    Dallas, Texas 75231, United States
  • Research Site
    Nadarzyn, Mazowieckie, Poland
  • Research Site
    Siedlce, Mazowieckie, Poland
  • Research Site
    Krakow, Małopolskie, Poland
  • Research Site
    Bialystok, Podlaskie, Poland
  • Research Site
    Elblag, Warmińsko-mazurskie, Poland
  • Research Site
    Poznan, Wielkopolskie, Poland
  • Research Site
    Warszawa, Poland
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2019 to primary completion in Dec 2021, 24 months.

Results were first posted in Feb 2023, 1 year 1 month after primary completion.

Of 116 industry-sponsored phase 2 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 24. This study's 24 months is above that.

Counting every sponsor, half of 158 studies reached it within 18 months; a quarter within 13 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2019
First posted
Nov 15, 2019
StartActual
Dec 9, 2019
Primary completionActual
Dec 28, 2021
CompletionActual
Dec 28, 2021
Results first posted
Feb 14, 2023
Last update
Dec 17, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 17, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04163991
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Nov 15, 2019
Start date
Dec 9, 2019
Primary completion
Dec 28, 2021
Completion
Dec 28, 2021
Results posted
Feb 14, 2023
Last update
Dec 17, 2024

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dazodalibep

Start the discussion